JP2025508665A5 - - Google Patents
Info
- Publication number
- JP2025508665A5 JP2025508665A5 JP2024543900A JP2024543900A JP2025508665A5 JP 2025508665 A5 JP2025508665 A5 JP 2025508665A5 JP 2024543900 A JP2024543900 A JP 2024543900A JP 2024543900 A JP2024543900 A JP 2024543900A JP 2025508665 A5 JP2025508665 A5 JP 2025508665A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- sequence
- acid sequence
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210110349.5 | 2022-01-29 | ||
| CN202210110349 | 2022-01-29 | ||
| PCT/CN2023/073057 WO2023143351A1 (zh) | 2022-01-29 | 2023-01-19 | 糖皮质激素的药物偶联物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508665A JP2025508665A (ja) | 2025-04-10 |
| JP2025508665A5 true JP2025508665A5 (enExample) | 2026-01-23 |
Family
ID=87470772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543900A Pending JP2025508665A (ja) | 2022-01-29 | 2023-01-19 | グルココルチコイドの薬物複合体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250152722A1 (enExample) |
| EP (1) | EP4470569A1 (enExample) |
| JP (1) | JP2025508665A (enExample) |
| KR (1) | KR20240134329A (enExample) |
| CN (1) | CN118678972A (enExample) |
| CA (1) | CA3248953A1 (enExample) |
| MX (1) | MX2024009080A (enExample) |
| TW (1) | TW202340252A (enExample) |
| WO (1) | WO2023143351A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202432588A (zh) | 2022-12-28 | 2024-08-16 | 大陸商蘇州盛迪亞生物醫藥有限公司 | 一種cd40結合分子的組成物及醫藥用途 |
| CN121568722A (zh) * | 2023-07-28 | 2026-02-24 | 江苏恒瑞医药股份有限公司 | 一种含有糖皮质激素的抗体药物偶联物的药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| DK2990420T3 (en) | 2000-05-26 | 2017-04-03 | Immunex Corp | USE OF INTERLEUKIN-4 RECEPTOR ANTIBODIES AND COMPOSITIONS THEREOF |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| MY149079A (en) | 2006-10-02 | 2013-07-15 | Regeneron Pharma | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US9574004B2 (en) | 2012-08-21 | 2017-02-21 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| TWI641620B (zh) * | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US11510993B2 (en) * | 2015-10-06 | 2022-11-29 | Merck Sharp & Dohme Llc | Antibody drug conjugate for anti-inflammatory applications |
| US20180126000A1 (en) * | 2016-06-02 | 2018-05-10 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
| BR112020010694A2 (pt) | 2017-12-01 | 2020-11-10 | Abbvie Inc. | agonista de receptor de glicocorticoides e imunoconjugados do mesmo |
| SG11202006510XA (en) | 2018-01-08 | 2020-08-28 | Regeneron Pharma | Steroids and antibody-conjugates thereof |
| US12162944B2 (en) | 2018-08-24 | 2024-12-10 | Jiangsu Hengrui Medicine Co., Ltd. | Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof |
| BR112021013464A2 (pt) * | 2019-01-08 | 2021-09-21 | Regeneron Pharmaceuticals, Inc. | Ligantes sem traço e conjugados de proteína dos mesmos |
| US20220193191A1 (en) | 2019-03-29 | 2022-06-23 | Astrazeneca Ab | Lipocalin mutein for treatment of asthma |
| JP7821733B2 (ja) * | 2020-01-22 | 2026-02-27 | 上海森輝医薬有限公司 | エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用 |
| CA3207416A1 (en) * | 2021-02-04 | 2022-08-11 | Lingjian ZHU | Drug conjugate of glucocorticoid receptor agonist, and application thereof in medicine |
-
2023
- 2023-01-19 MX MX2024009080A patent/MX2024009080A/es unknown
- 2023-01-19 CA CA3248953A patent/CA3248953A1/en active Pending
- 2023-01-19 US US18/833,773 patent/US20250152722A1/en active Pending
- 2023-01-19 JP JP2024543900A patent/JP2025508665A/ja active Pending
- 2023-01-19 KR KR1020247025079A patent/KR20240134329A/ko active Pending
- 2023-01-19 CN CN202380015740.XA patent/CN118678972A/zh active Pending
- 2023-01-19 TW TW112102805A patent/TW202340252A/zh unknown
- 2023-01-19 WO PCT/CN2023/073057 patent/WO2023143351A1/zh not_active Ceased
- 2023-01-19 EP EP23746232.0A patent/EP4470569A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7467610B2 (ja) | カンプトテシン誘導体及びその複合体 | |
| US20240173427A1 (en) | Glypican 3 antibodies and conjugates thereof | |
| JP2023535598A5 (enExample) | ||
| JP5782479B2 (ja) | ＰＥＧ化ＡβＦＡＢ | |
| JP2019031565A5 (enExample) | ||
| CA3175733A1 (en) | Pharmaceutical composition comprising antibody drug conjugate and use thereof | |
| JP2025508665A5 (enExample) | ||
| JP2024501894A5 (enExample) | ||
| JP2020532562A (ja) | 生物学的製剤の粘度を低下させるための化合物 | |
| JP2025524637A (ja) | 抗体薬物複合体及びその調製方法並びに使用 | |
| JP2021525059A5 (enExample) | ||
| WO2023124963A1 (zh) | 一种可逆反应减少的抗体-药物偶联物，其制备方法及应用 | |
| CN118475367A (zh) | 用于治疗和预防covid-19的组合物 | |
| CN115501347A (zh) | 抗her2抗体药物偶联物和parp抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2023536155A5 (enExample) | ||
| JP2025535263A (ja) | 組成物およびその使用 | |
| JP2025504419A (ja) | 抗ＣＤ７９ｂ抗体薬物複合体を含む医薬組成物及びその使用 | |
| RU2024124223A (ru) | Конъюгат на основе глюкокортикоидного лекарственного средства | |
| JP7594708B1 (ja) | ネクチン４を標的としエキサテカンペイロードを含む抗体薬物コンジュゲート（ａｄｃ） | |
| RU2858285C2 (ru) | Производное каптотецина и его конъюгат | |
| RU2840147C1 (ru) | Фармацевтическая композиция, содержащая конъюгат антитела и лекарственного средства, и ее применение | |
| RU2833323C1 (ru) | Конъюгат антитела против cea и аналога эксатекана и его фармацевтическое применение | |
| RU2025113325A (ru) | Конъюгат антитело-лекарственное средство, включающий анти-клаудин-18.2 антитело, и его применение в терапии рака | |
| TW202527994A (zh) | 一種抗病毒偶聯物 | |
| WO2026092698A1 (zh) | 一种抗体-药物偶联物及其制备方法和用途 |